Latest
News
Jane E. Brody of the New York Times writes about witnessing the 'miraculous' transformation in her friend's asthma after learning the Buteyko method. To read the full article go to the New York Times website:
http://www.nytimes.com/2009/11/03/health/03brod.html
FDA Panel decides asthma drugs - Serevent and Oxis - aren’t worth the risk
An FDA Panel said Thursday [December 11th 2008] that the risks of death and serious injury associated with two popular brands of asthma inhalers are greater than the benefits of the drugs. However, in what is sure to be a controversial opinion, the panel said that Advair (Symbicort) should continue to be used to treat asthma.
The FDA has previously said that Serevent, Foradil (sold as Oxis in NZ), and similar drugs are linked to an increased risk of asthma-related side effects, particularly in children and the elderly. The side effects have resulted in injuries including asthma-related death, hospitalization, and asthma-related intubations, where a tube must be placed in patients’ noses or mouths to help them breathe.
The agency found an additional 2.8 asthma events per 1,000 patients treated with a LABA compared with patients not receiving the drugs. Note: Long-acting beta agonists (LABAS) are sold in NZ as Serevent, Oxis, and in combination with inhaled corticosteroid asthma drugs as Symbicort and Seretide.
For full story: http://www.attorneyatlaw.com/2008/12/fda-panel-serevent-foradil-aren%E2%80%99t-worth-risk-but-backs-advair/
Buteyko Asthma Endorsement UK
It surprises many people to learn that, according to medical literature, no other treatment for asthma has ever achieved better results than Buteyko's Method. This is now supported by the British Guideline on the Management of Asthma 2008 granting permission for British health professionals to recommend Buteyko, stating that the method "may be considered to help patients control the symptoms of asthma". The guideline also grades clinical research on Buteyko with a 'B' classification - indicating that high-quality supporting clinical trials are available. No other complementary therapy has been endorsed by this body for the treatment of asthma.
British Thoracic Society & Scottish Intercollegiate Guidelines Network (SIGN). British Guideline on the Management of Asthma. Guideline No. 101. Edinburgh:SIGN; 2008.
Irish hospital study - Buteyko Effective in reducing symptoms of Hay fever
Preliminary results of a study at Limerick Hospital in Ireland suggest the Buteyko Method is effective in reducing the symptoms associated with allergic rhinitis (hay fever). Preliminary results show a 75-80% improvement in nasal symptoms which persists at 3 month follow-up as long as the patients continue the exercises. The study is nearing completion. Professor John Fenton ENT consultant at Limerick hospital proposed the study after observing substantial improvements in his patients after they had attended Buteyko programmes at the asthma care clinic in Limerick.
January
2008 – Are you a healthy breather?
Click
here to find out.
Press release for World
Asthma
Day 1st May 2007
:
Scoop
Independent News
Follow this link to view a programme
on Buteyko that screened on Australian TV 19th March 2007
http://health.ninemsn.com.au/article.aspx?id=255439
Follow this link to view the Campbell live TV feature
on Buteyko that aired May and June 2006
http://www.tv3.co.nz/VideoBrowseAll/CampbellLive/tabid/367/articleID/9600/Default.aspx
